P2.01-41 the Role and Mechanism of FBW7 Deficiency in Advanced Non-Small Cell Lung Cancer With Docetaxel Resistance

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.1095
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

P2.01-12 Ramucirumab+Docetaxel Usage Following Rapid Disease Progression in Real World Advanced Non-Small Cell Lung Cancer Patients

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P2.01-131 Apatinib as an Alternative for Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Potential Role of Immunotherapy in Advanced Non-Small-Cell Lung Cancer

OncoTargets and Therapy
OncologyPharmacology
2016English

Non-Small Cell Lung Cancer-Small Cell Lung Cancer Transformation as Mechanism of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer

2020English

Analysis of Continuous First‑line Treatment With Docetaxel and Carboplatin for Advanced Non‑small Cell Lung Cancer

Oncology Letters
Cancer ResearchOncology
2014English

Management of Patients With Advanced Non-Small Cell Lung Cancer: Role of Gefitinib

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2010English

Triplet Chemotherapy Combination With Cisplatin, Gemcitabine and Docetaxel in Patients With Chemotherapy‑naive Advanced Non-Small Cell Lung Cancer

Oncology Letters
Cancer ResearchOncology
2013English

Targeting FBW7 as a Strategy to Overcome Resistance to Targeted Therapy in Non–Small Cell Lung Cancer

Cancer Research
Cancer ResearchOncology
2017English

P2.01-017 Study on the Effect of Apatinib Salvage Treatment of Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy